Tue, 26th Jan 2021 20:34
Jan 26 (Reuters) - AstraZeneca Chief Executive
Pascal Soriot said on Tuesday that the British drugmaker is
working with Oxford University on a vaccine that will target the
South African variant of COVID-19.
"Having said that, we're also working on a vaccine with
Oxford University that will target the variant," Soriot told
Italian daily La Repubblica in an interview https://bit.ly/2KWidAc
published late on Tuesday.
(Reporting by Kanishka Singh in Bengaluru; Editing by Leslie
Adler)
(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:
(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump...
(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth readi...
(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover ta...
Q1 revenue up 19% to $12.68 bln *
Astrazeneca (AZN)